AU2012360168C1 - Vaccines directed against human Enteroviruses - Google Patents

Vaccines directed against human Enteroviruses Download PDF

Info

Publication number
AU2012360168C1
AU2012360168C1 AU2012360168A AU2012360168A AU2012360168C1 AU 2012360168 C1 AU2012360168 C1 AU 2012360168C1 AU 2012360168 A AU2012360168 A AU 2012360168A AU 2012360168 A AU2012360168 A AU 2012360168A AU 2012360168 C1 AU2012360168 C1 AU 2012360168C1
Authority
AU
Australia
Prior art keywords
enterovirus
human
expression
hev71
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012360168A
Other languages
English (en)
Other versions
AU2012360168B2 (en
AU2012360168A2 (en
AU2012360168A1 (en
Inventor
Mary Jane Cardosa
Sharifah Binti Hamid
Mohamad Fakruddin Jamiluddin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SENTINEXT THERAPEUTICS Sdn Bhd
Original Assignee
SENTINEXT THERAPEUTICS Sdn Bhd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SENTINEXT THERAPEUTICS Sdn Bhd filed Critical SENTINEXT THERAPEUTICS Sdn Bhd
Publication of AU2012360168A1 publication Critical patent/AU2012360168A1/en
Publication of AU2012360168A2 publication Critical patent/AU2012360168A2/en
Publication of AU2012360168B2 publication Critical patent/AU2012360168B2/en
Application granted granted Critical
Publication of AU2012360168C1 publication Critical patent/AU2012360168C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2012360168A 2011-11-03 2012-11-01 Vaccines directed against human Enteroviruses Ceased AU2012360168C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
MYPI2011005318 2011-11-03
MYPI2011005318 2011-11-03
PCT/IB2012/003114 WO2013098655A2 (en) 2011-11-03 2012-11-01 Antigens and vaccines directed against human enteroviruses

Publications (4)

Publication Number Publication Date
AU2012360168A1 AU2012360168A1 (en) 2014-05-22
AU2012360168A2 AU2012360168A2 (en) 2015-04-30
AU2012360168B2 AU2012360168B2 (en) 2017-06-22
AU2012360168C1 true AU2012360168C1 (en) 2017-09-28

Family

ID=47215776

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012360168A Ceased AU2012360168C1 (en) 2011-11-03 2012-11-01 Vaccines directed against human Enteroviruses

Country Status (16)

Country Link
US (3) US9987350B2 (enExample)
EP (2) EP3290050B1 (enExample)
JP (2) JP6190378B2 (enExample)
KR (3) KR101900460B1 (enExample)
CN (2) CN107441484A (enExample)
AU (1) AU2012360168C1 (enExample)
BR (1) BR112014010658A2 (enExample)
CA (1) CA2854594C (enExample)
CL (1) CL2014001160A1 (enExample)
HK (2) HK1245128A1 (enExample)
MX (2) MX363409B (enExample)
MY (1) MY172501A (enExample)
PH (2) PH12014501041B1 (enExample)
SG (1) SG11201401998VA (enExample)
TW (2) TWI626308B (enExample)
WO (1) WO2013098655A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI700295B (zh) 2013-12-16 2020-08-01 馬來西亞商Ｍａｂ探索私人有限公司 對會感染人類之腸病毒具有專一性之抗體
DK3134131T3 (en) 2014-04-23 2022-02-07 Modernatx Inc Nucleic acid vaccines
KR20170068410A (ko) * 2014-04-29 2017-06-19 내셔날 헬스 리서치 인스티튜트 엔테로바이러스 감염증에 대항하는 아데노바이러스 벡터-기반 백신
CN111925423B (zh) * 2014-11-07 2022-08-19 普莱柯生物工程股份有限公司 一种抗o型口蹄疫的疫苗组合物及其制备方法和应用
CN106554965B (zh) * 2015-09-28 2019-08-27 斯澳生物科技（苏州）有限公司 用于制备ev71病毒样颗粒的核酸构建体和方法
CN105348391B (zh) * 2015-11-03 2019-06-28 李越希 埃可病毒6型vp1蛋白特异性抗原表位及其融合蛋白的制备、应用
CN105802923B (zh) * 2016-04-14 2019-07-16 中国科学院生物物理研究所 一种重组脊髓灰质炎病毒样颗粒及其制备方法与应用
MX392073B (es) * 2016-04-22 2025-03-21 Integrated Res Associates Llc Metodo mejorado para producir particulas similares a virus
US20190224304A1 (en) * 2016-10-07 2019-07-25 Sentinext Therapeutics Sdn Bhd Chimeric enterovirus virus-like particles
WO2018067000A1 (en) 2016-10-07 2018-04-12 Sentinext Therapeutics Sdn Bhd Expression cassettes and methods for obtaining enterovirus virus-like particles
KR102091372B1 (ko) 2017-02-28 2020-05-27 대한민국 엔테로바이러스 71형 불활화 백신 및 이의 용도
CN108624601B (zh) * 2017-03-17 2023-08-11 中国科学院上海巴斯德研究所 酵母表达的柯萨奇病毒a10病毒样颗粒及其应用
AU2018298499B2 (en) * 2017-07-03 2024-07-18 Bharat Biotech International Limited A synthetic polypeptide epitope based vaccine composition
CN108152511B (zh) * 2017-12-20 2019-01-04 广州瑞辉生物科技股份有限公司 柯萨奇A16病毒抗原多肽及其IgM抗体检测试剂盒
CN108424881B (zh) * 2018-03-23 2021-07-27 中国食品药品检定研究院 一株肠道病毒68型及其在制备ev-d68型感染动物中的应用
WO2020067027A1 (ja) * 2018-09-28 2020-04-02 一般財団法人阪大微生物病研究会 Ｖｌｐ発現ｃｈｏ細胞株の構築
CN110045105B (zh) * 2018-11-09 2022-04-26 广州市妇女儿童医疗中心 柯萨奇A16病毒IgA抗体量子点免疫荧光层析试纸条及试剂盒
WO2020132595A1 (en) * 2018-12-21 2020-06-25 The Regents Of The University Of California Il-10-containing vaccines and uses thereof
CN110684781B (zh) * 2019-06-24 2021-05-28 四川农业大学 一种3型鸭甲肝病毒突变基因isa-a117c-t1142a及构建方法
CN112048004B (zh) * 2020-07-14 2021-10-22 桂林医学院 一种柯萨奇病毒b5型病毒样颗粒、其制备方法及应用
WO2022070210A1 (en) * 2020-09-29 2022-04-07 Bharat Biotech International Limited Stable formulations of low abundance enteroviruses vaccines and process of manufacture thereof
CN114107392A (zh) * 2021-11-22 2022-03-01 昆明理工大学 一种cvb5病毒类病毒样颗粒的制备方法
CN115010813B (zh) * 2022-05-19 2024-04-05 桂林医学院 一种肠道病毒71型病毒样颗粒、其制备方法及应用
CN116200348A (zh) * 2022-09-21 2023-06-02 武汉生物制品研究所有限责任公司 一种适应Vero细胞的柯萨奇病毒A10型毒株的构建方法及其应用
US11826418B1 (en) 2023-01-06 2023-11-28 King Faisal University Virus-like particle (VLP)-based vaccine against CVB4
WO2025029700A1 (en) * 2023-07-28 2025-02-06 Modernatx, Inc. Vlp enteroviral vaccines
CN117456519B (zh) * 2023-12-22 2024-03-12 江西科益高新技术有限公司 一种用于工控安全的仿真光电靶标装置及其仿真方法
CN120665160B (zh) * 2025-08-21 2026-03-20 国药中生生物技术研究院有限公司 肠道病毒71型的突变体及其病毒样颗粒

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8102740A (nl) 1981-06-05 1983-01-03 Nederlanden Staat Virusvaccins en werkwijze ter bereiding daarvan.
WO2003046138A2 (en) 2001-11-26 2003-06-05 Duke University Genetically stable expression vector
US20050112095A1 (en) * 2002-07-09 2005-05-26 Tsu-An Hsu Internal ribosome entry sites for recombinant protein expression
EP1479761A1 (en) * 2003-05-21 2004-11-24 PrimaGen Holding B.V. New enterovirus, vaccines, medicaments and diagnostic kits
ES2310062B1 (es) * 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
WO2007052163A2 (en) * 2005-11-01 2007-05-10 Novartis Vaccines And Diagnostics Gmbh & Co Kg Cell-derived viral vaccines with low levels of residual cell dna by beta-propiolactone treatment
US20100143406A1 (en) * 2006-06-30 2010-06-10 Gale Smith Methods of enhancing protein incorporation into virus like particles
AU2009286956B2 (en) * 2008-08-28 2012-12-06 Novartis Ag Cell surface display of polypeptide isoforms by stop codon readthrough
US8663951B2 (en) * 2009-01-09 2014-03-04 Academia Sinica Method of producing virus-like particles of picornavirus using a small-ubiquitin-related fusion protein expression system
CN101831410B (zh) 2009-03-09 2013-04-17 北京工业大学 重组肠病毒71型病毒样颗粒的制备方法
GB0918375D0 (en) 2009-10-20 2009-12-02 Animal Health Inst Construct
CN103562389B (zh) * 2011-02-08 2020-06-23 淡马锡生命科学研究院有限公司 用于有效表面展示抗原蛋白的新颖表达盒

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHUNG Y-C, et al. "Expression, purification and characterization of enterovirus-71 virus-like particles." World J Gastroenterol. 2006 Feb 14;12(6):921-7. *
CHUNG, C-Y et al. "Enterovirus 71 virus-like particle vaccine: Improved production conditions for enhanced yield." Vaccine. 2010 Oct 8;28(43):6951-7. doi: 10.1016/j.vaccine.2010.08.052. Epub 2010 Aug 24. *
CHUNG, Y-C. et al. "Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge." Vaccine. 2008 Mar 28;26(15):1855-62. doi: 10.1016/j.vaccine.2008.01.058. Epub 2008 Feb *
HU, Y-C. et al. "Formation of enterovirus-like particle aggregates by recombinant baculoviruses co-expressing P1 and 3CD in insect cells." Biotechnol Lett. 2003 Jun;25(12):919-25 *
MATRAHIM, N.A. et al. "DNA Vaccine Construct in the Presence of EV71 IRES Elicited Higher Neutralizing Antibody Titre." 13th International Congress on Infectious Diseases, Abstracts, Poster Presentations, Dec 2008. Vol 12, Sup 1, Page e254. *

Also Published As

Publication number Publication date
WO2013098655A9 (en) 2013-12-19
AU2012360168B2 (en) 2017-06-22
US10548964B2 (en) 2020-02-04
EP2773372B1 (en) 2018-12-26
US20180243400A1 (en) 2018-08-30
CA2854594A1 (en) 2013-07-04
MX363409B (es) 2019-03-20
KR20140096343A (ko) 2014-08-05
KR101900460B1 (ko) 2018-11-08
PH12014501041A1 (en) 2014-08-04
TWI571512B (zh) 2017-02-21
CN104093420A (zh) 2014-10-08
MX2014005315A (es) 2015-03-09
KR20170109700A (ko) 2017-09-29
EP2773372A2 (en) 2014-09-10
MX2018013782A (es) 2021-12-08
TWI626308B (zh) 2018-06-11
KR20180104201A (ko) 2018-09-19
JP2017226677A (ja) 2017-12-28
PH12014501041B1 (en) 2014-08-04
EP3290050B1 (en) 2019-01-02
US9987350B2 (en) 2018-06-05
PH12019500289A1 (en) 2020-02-17
US20150140027A1 (en) 2015-05-21
US20180271971A1 (en) 2018-09-27
KR102002103B1 (ko) 2019-07-19
AU2012360168A2 (en) 2015-04-30
CL2014001160A1 (es) 2014-11-03
HK1245128A1 (zh) 2018-08-24
AU2012360168A1 (en) 2014-05-22
CN107441484A (zh) 2017-12-08
MY172501A (en) 2019-11-27
JP6419271B2 (ja) 2018-11-07
SG11201401998VA (en) 2014-05-29
HK1202803A1 (en) 2015-10-09
TW201716576A (zh) 2017-05-16
TW201333195A (zh) 2013-08-16
CN104093420B (zh) 2017-07-28
BR112014010658A2 (pt) 2017-06-13
KR101782451B1 (ko) 2017-09-29
JP2014532691A (ja) 2014-12-08
EP3290050A1 (en) 2018-03-07
HK1251492B (en) 2019-10-25
WO2013098655A3 (en) 2013-09-12
JP6190378B2 (ja) 2017-08-30
WO2013098655A2 (en) 2013-07-04
CA2854594C (en) 2018-08-21
US10555997B2 (en) 2020-02-11

Similar Documents

Publication Publication Date Title
US10548964B2 (en) Antigens and vaccines directed against human enteroviruses
HK1251492A1 (en) Vaccines directed against human enteroviruses
US20150056244A1 (en) Antigens and Vaccines Directed Against Human Enteroviruses
US20100086564A1 (en) West Nile Virus Vaccine
JP6818548B2 (ja) ワクチンにおけるデングウイルスキメラ構築物に関する組成物および方法
CN111961654B (zh) 耐热表型稳定遗传、携带负标记的重组口蹄疫病毒无毒株及o/a型口蹄疫二价灭活疫苗
US20190247488A1 (en) Expression cassettes and methods for obtaining enterovirus virus-like particles
RU2215035C2 (ru) Рекомбинантный полиовирусный вектор (варианты), способ его получения (варианты), способ индукции иммунного ответа у индивидуума (варианты), способ получения белка (варианты), вакцинная композиция для терапии или профилактики инфекционных заболеваний (варианты)
HK1202803B (en) Antigens and vaccines directed against human enteroviruses
TW201825675A (zh) 用於獲得腸病毒病毒樣顆粒之表現匣及方法
TW201825676A (zh) 嵌合型腸病毒病毒樣顆粒

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20 MAR 2015

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 JUN 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 JUN 2017

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired